The eosinophilia-myalgia syndrome (EMS) is a rare systemic disease caused by presumably contaminated L-tryptophan. Thirteen outpatients with EMS were found to have a high degree of depression, anxiety, and difficulty adjusting to illness. Pre-EMS history of major depression but not EMS severity predicted poor adjustment to illness.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0033-3182(95)71703-0DOI Listing

Publication Analysis

Top Keywords

eosinophilia-myalgia syndrome
8
psychiatric aspects
4
aspects eosinophilia-myalgia
4
syndrome eosinophilia-myalgia
4
syndrome ems
4
ems rare
4
rare systemic
4
systemic disease
4
disease caused
4
caused presumably
4

Similar Publications

Article Synopsis
  • Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
  • Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
  • Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
View Article and Find Full Text PDF
Article Synopsis
  • * A study was conducted on pigs to evaluate the potential risks of using L-tryptophan as a feed additive, focusing on general toxicity and EMS-related symptoms.
  • * Results showed no toxic effects or EMS symptoms in the pigs, indicating that L-tryptophan and its impurities do not pose safety concerns, allowing its continued use in swine diets throughout all growth stages.
View Article and Find Full Text PDF
Article Synopsis
  • B-cell acute lymphoblastic leukemia (B-ALL) associated with eosinophilia (ALL-eo) is a rare condition, typically marked by the absence of blast cells in peripheral blood and symptoms like rash, fever, and dyspnea.
  • A 16-year-old male presented with generalized itching and urticaria; blood tests showed 90% eosinophils but no blasts.
  • Diagnosis was confirmed through a bone marrow examination revealing lymphoid blasts, and the patient was treated with the Berlin-Frankfurt-Münster chemotherapy regimen.
View Article and Find Full Text PDF
Article Synopsis
  • Dupilumab blocks the IL-4/IL-13 pathway, leading to increased eosinophils in the blood, which can potentially contribute to chronic eosinophilic pneumonia (CEP) but no direct link has been established.
  • A 33-year-old woman with a history of asthma and previous CEP experienced multiple asthma exacerbations and a recurrence of CEP despite steroid treatment.
  • After starting dupilumab, her asthma symptoms improved significantly, and she didn't experience any further asthma exacerbations or CEP relapses over a 12-month period, suggesting it may be an effective option for similar patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!